Markets

FDA Gives Clearance To TuHURA Biosciences' IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related Cancers

Sep 14, 2026 · 07:49 AM ET· updated 51m ago

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that

Why It Matters

TuHURA got permission to test a new cancer medicine in people. This is a normal step forward that shows the company is progressing with its research.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

HURA2.05

+0.00 (+0.05%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.